X

Trial Profile

Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clostridium difficile vaccine (Primary)
Indications Clostridium difficile infections
Focus Registrational; Therapeutic Use
Acronyms Cdiffense
Sponsors Sanofi Pasteur

Most Recent Events

03 Aug 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.
06 Feb 2019 This study has been completed in United Kingdom.
05 Feb 2018 Planned End Date changed from 1 Oct 2019 to 16 May 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com